Revelation Biosciences (NASDAQ:REVB) Issues Quarterly Earnings Results

Revelation Biosciences (NASDAQ:REVB) posted its quarterly earnings results on Thursday. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.41) by ($0.24), FiscalAI reports.

Revelation Biosciences Price Performance

Shares of Revelation Biosciences stock traded down $0.01 during trading on Friday, hitting $1.32. 65,539 shares of the stock were exchanged, compared to its average volume of 261,178. The stock has a market cap of $9.11 million, a price-to-earnings ratio of -0.02 and a beta of -0.11. The firm’s 50-day moving average price is $2.53 and its 200 day moving average price is $4.92. Revelation Biosciences has a 12-month low of $1.29 and a 12-month high of $46.31.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Revelation Biosciences in a report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Institutional Trading of Revelation Biosciences

An institutional investor recently bought a new position in Revelation Biosciences stock. Geode Capital Management LLC acquired a new position in shares of Revelation Biosciences, Inc. (NASDAQ:REVB) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 34,019 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned about 2.15% of Revelation Biosciences at the end of the most recent quarter. 12.80% of the stock is owned by institutional investors.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.